Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results
Amylyx reported a Q2 net loss of $43.4 million, or $0.39 per share, compared to a loss of $41.4 million a year ago, with R&D expenses decreasing to $23.8 million and SG&A rising to $21.9 million driven by legal costs. The company confirmed the final patient visit in the Phase 3 LUCIDITY trial of avexitide, with topline data anticipated in late August or early September 2026.
Key figures
- Rd expenses
- 23800000
- Sga expenses
- 21900000
- Cash position
- 250800000
- Net loss
- 43400000
- Cash runway
- into 2028
- Trial participants
- 78
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.